

# Olatunji B Alese

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1475397/publications.pdf>

Version: 2024-02-01

71  
papers

1,814  
citations

411340

20  
h-index

340414

39  
g-index

75  
all docs

75  
docs citations

75  
times ranked

3242  
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors Affecting Inpatient Mortality and Length of Stay in Nonmetastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, 45, 14-21.	0.6	1
2	Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. Oncology, 2022, 100, 131-139.	0.9	5
3	Characteristics and outcomes of patients with multiple synchronous colon cancer primaries.. Journal of Clinical Oncology, 2022, 40, 194-194.	0.8	0
4	A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS375-TPS375.	0.8	4
5	Impact of local therapy on survival among patients with metastatic anal squamous cell carcinoma.. Journal of Clinical Oncology, 2022, 40, 4-4.	0.8	0
6	Cancer healthcare disparities among African Americans in the United States. Journal of the National Medical Association, 2022, 114, 236-250.	0.6	14
7	Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer. Oncologist, 2022, 27, 740-750.	1.9	2
8	Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 279-298.	1.8	11
9	Telotristat ethyl with PRRT in the treatment of well differentiated neuroendocrine tumors.. Journal of Clinical Oncology, 2022, 40, e16205-e16205.	0.8	1
10	Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival. Oncotarget, 2022, 13, 828-841.	0.8	9
11	Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix?. Surgical Oncology, 2021, 36, 120-129.	0.8	7
12	Perioperative therapy in metastatic colorectal cancer: Pattern of use and survival outcomes. Journal of Surgical Oncology, 2021, 123, 596-605.	0.8	3
13	Phase II trial of nivolumab and metformin in patients with treatment refractory microsatellite stable metastatic colorectal cancer.. Journal of Clinical Oncology, 2021, 39, 95-95.	0.8	5
14	Survival outcomes of adjuvant chemotherapy in elderly patients with stage III colon cancer.. Journal of Clinical Oncology, 2021, 39, 89-89.	0.8	0
15	Impact of high-risk features for stage II adenocarcinoma of the appendix. Cancer Treatment and Research Communications, 2021, 27, 100329.	0.7	1
16	A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 2470-2480.	3.2	51
17	Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status. Frontiers in Oncology, 2021, 11, 592351.	1.3	9
18	Survival Outcomes of Acinar Cell Pancreatic Cancer. Pancreas, 2021, 50, 529-536.	0.5	1

#	ARTICLE	IF	CITATIONS
19	Clinical features and outcomes of colloid carcinoma of pancreas compared to pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2021, 39, e16259-e16259.	0.8	0
20	A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations.. Journal of Clinical Oncology, 2021, 39, TPS3159-TPS3159.	0.8	0
21	Treatment outcomes for stage T1b-2 esophagogastric adenocarcinomas.. Journal of Clinical Oncology, 2021, 39, e16085-e16085.	0.8	0
22	Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review. Clinical Colorectal Cancer, 2021, 20, 153-160.	1.0	3
23	Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 74-81.	0.6	36
24	High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer. Frontiers in Oncology, 2021, 11, 755113.	1.3	7
25	Role of Resection of the Primary in Metastatic Well-Differentiated Neuroendocrine Tumors. Pancreas, 2021, 50, 1382-1391.	0.5	2
26	Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival. Frontiers in Oncology, 2021, 11, 728076.	1.3	10
27	Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer, 2020, 126, 575-582.	2.0	65
28	In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. Journal of Geriatric Oncology, 2020, 11, 660-667.	0.5	13
29	Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. Oncologist, 2020, 25, e528-e535.	1.9	44
30	Clinicopathological features and survival outcomes of rare histologic variants of gallbladder cancer. Journal of Surgical Oncology, 2020, 121, 294-302.	0.8	8
31	Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. Clinical Cancer Research, 2020, 26, 5329-5337.	3.2	6
32	Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 1632.	1.3	5
33	Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer. Cancer, 2020, 126, 4136-4147.	2.0	6
34	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. British Journal of Cancer, 2020, 123, 1228-1234.	2.9	6
35	Young Adults With Pancreatic Cancer. Pancreas, 2020, 49, 341-354.	0.5	12
36	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 2497-2505.	3.2	9

#	ARTICLE	IF	CITATIONS
37	Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 822-829.	0.5	2
38	Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers. <i>Oncologist</i> , 2020, 25, 414-421.	1.9	11
39	A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. <i>JAMA Oncology</i> , 2020, 6, 888.	3.4	293
40	Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. <i>Oncotarget</i> , 2020, 11, 1749-1757.	0.8	29
41	Comparison of physical activity as an obesity-related behavior between immigrants and native-born US adults. <i>Palgrave Communications</i> , 2020, 6, .	4.7	2
42	&lt;p&gt;Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma&lt;/p&gt;. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 119-129.	1.8	15
43	Analysis of racial disparities in the treatment and outcomes of colorectal cancer in young adults. <i>Cancer Epidemiology</i> , 2019, 63, 101618.	0.8	26
44	Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. <i>British Journal of Cancer</i> , 2019, 121, 809-818.	2.9	232
45	Optimizing cancer care for hepatocellular carcinoma at a safetyâ€net hospital: The value of a multidisciplinary disease management team. <i>Journal of Surgical Oncology</i> , 2019, 120, 1365-1370.	0.8	19
46	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. <i>BMC Cancer</i> , 2019, 19, 857.	1.1	88
47	US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials. <i>Journal of Oncology Practice</i> , 2019, 15, e289-e299.	2.5	63
48	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <i>Investigational New Drugs</i> , 2019, 37, 1198-1206.	1.2	11
49	Clinical Outcomes of Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2019, 18, 257-268.	1.0	24
50	Induction Therapy in Localized Pancreatic Cancer. <i>Pancreas</i> , 2019, 48, 913-919.	0.5	7
51	Rosai-Dorfman Disease of the Pancreas Shows Significant Histologic Overlap With IgG4-related Disease. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1536-1546.	2.1	13
52	High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. <i>Oncologist</i> , 2019, 24, 911-920.	1.9	39
53	Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. <i>Cancer</i> , 2019, 125, 57-67.	2.0	15
54	The prognostic and predictive impact of inflammatory biomarkers in patients who have advancedâ€stage cancer treated with immunotherapy. <i>Cancer</i> , 2019, 125, 127-134.	2.0	120

#	ARTICLE	IF	CITATIONS
55	Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. <i>Cancer</i> , 2018, 124, 1992-2000.	2.0	17
56	Analysis of Opioid Use Following Curative Cancer Treatment at a Large Urban Safety-net Hospital. <i>Clinical Journal of Pain</i> , 2018, 34, 885-889.	0.8	9
57	Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. <i>Oncologist</i> , 2018, 23, 704-711.	1.9	15
58	Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. <i>Journal of Gastrointestinal Oncology</i> , 2018, 10, 85-94.	0.6	24
59	Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. <i>Oncology</i> , 2018, 95, 138-146.	0.9	7
60	Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer. <i>Molecular Carcinogenesis</i> , 2017, 56, 288-299.	1.3	35
61	Appendiceal Mucinous Neoplasms: Diagnosis and Management. <i>Oncologist</i> , 2017, 22, 1107-1116.	1.9	131
62	Rosai-Dorfman Disease Manifesting as a Pancreatic Head Mass Diagnosed Nonoperatively. <i>Journal of Oncology Practice</i> , 2017, 13, 61-62.	2.5	7
63	Therapy-related acute myeloid leukemia following radioactive iodine treatment for thyroid cancer. <i>Cancer Causes and Control</i> , 2016, 27, 143-146.	0.8	10
64	Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. <i>Oncologist</i> , 2016, 21, 178-187.	1.9	47
65	Rasburicase-induced methaemoglobinaemia and G6PD deficiency in an unusual suspect. <i>British Journal of Haematology</i> , 2015, 170, 595-595.	1.2	8
66	Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States. <i>World Journal of Oncology</i> , 2015, 6, 349-354.	0.6	0
67	Management patterns and predictors of mortality among US patients with cancer hospitalized for malignant bowel obstruction. <i>Cancer</i> , 2015, 121, 1772-1778.	2.0	26
68	Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 56-62.	1.4	18
69	HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. <i>Oncotarget</i> , 2014, 5, 9980-9991.	0.8	52
70	Pyoderma gangrenosum and ulcerative colitis in the tropics. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2008, 41, 664-667.	0.4	5
71	On-Site Physicians at a Major Sporting Event in Nigeria. <i>Prehospital and Disaster Medicine</i> , 2006, 21, 40-44.	0.7	20